Effectiveness of Ocrelizumab on Disease Progression and Disability Status in Multiple Sclerosis Patients: A Two-Year Prospective Cohort Study DOI Open Access

Amanda Claudia Schuldesz,

Raluca Tudor, Amalia Cornea

и другие.

Journal of Clinical Medicine, Год журнала: 2025, Номер 14(2), С. 553 - 553

Опубликована: Янв. 16, 2025

Background and Objectives: Multiple sclerosis (MS) is a chronic autoimmune disorder characterized by inflammation neurodegeneration. Ocrelizumab, humanized anti-CD20 monoclonal antibody, has shown promise in reducing disease activity MS patients. This prospective study aims to assess the effectiveness of ocrelizumab confirmed disability progression patients with relapsing-remitting (RRMS) secondary progressive (SPMS) over two-year period. By evaluating clinical data, MRI findings, this seeks provide comprehensive insights into ocrelizumab's impact on dynamics disability. Materials Methods: Ninety-eight aged 18 65 were enrolled under therapy at Neurology Department "Pius Brinzeu" Clinical Emergency Hospital Romania between July 2020 2024. Participants assessed baseline every six months two years. The key outcomes measured changes Expanded Disability Status Scale (EDSS) as measure (CDP), annualized relapse rate (ARR), findings. Results: Over period, mean EDSS score significantly decreased from 5.2 ± 1.8 4.6 1.7 (mean change = -0.6 0.9; p 0.032), indicating improved neurological function. proportion experiencing relapses dropped markedly 61.2% 14.3% (p < 0.001). results showed significant reductions new or enlarging T2 lesions 68.4% 27.6% 0.001) gadolinium-enhancing 44.9% 15.3% Patients previously treated natalizumab exhibited greater reduction scores (-1.0 0.8; compared other treatments. Multivariate regression identified (β 0.65; 0.001), previous use -0.30; 0.013), age diagnosis 0.02; 0.048) predictors scores. While markers active decreased, brain atrophy increased 31.6% 43.9% (not statistically significant; 0.105). SPMS had higher rates (61.1% vs. 25.0%; 0.007) years (100.0% 31.3%; RRMS Conclusions: Ocrelizumab effectively reduced both Significant observed. Previous treatment was associated improvements. Despite these benefits, neurodegeneration, particularly patients, underscores need for additional strategies targeting neurodegenerative aspects MS.

Язык: Английский

Effectiveness of Ocrelizumab on Disease Progression and Disability Status in Multiple Sclerosis Patients: A Two-Year Prospective Cohort Study DOI Open Access

Amanda Claudia Schuldesz,

Raluca Tudor, Amalia Cornea

и другие.

Journal of Clinical Medicine, Год журнала: 2025, Номер 14(2), С. 553 - 553

Опубликована: Янв. 16, 2025

Background and Objectives: Multiple sclerosis (MS) is a chronic autoimmune disorder characterized by inflammation neurodegeneration. Ocrelizumab, humanized anti-CD20 monoclonal antibody, has shown promise in reducing disease activity MS patients. This prospective study aims to assess the effectiveness of ocrelizumab confirmed disability progression patients with relapsing-remitting (RRMS) secondary progressive (SPMS) over two-year period. By evaluating clinical data, MRI findings, this seeks provide comprehensive insights into ocrelizumab's impact on dynamics disability. Materials Methods: Ninety-eight aged 18 65 were enrolled under therapy at Neurology Department "Pius Brinzeu" Clinical Emergency Hospital Romania between July 2020 2024. Participants assessed baseline every six months two years. The key outcomes measured changes Expanded Disability Status Scale (EDSS) as measure (CDP), annualized relapse rate (ARR), findings. Results: Over period, mean EDSS score significantly decreased from 5.2 ± 1.8 4.6 1.7 (mean change = -0.6 0.9; p 0.032), indicating improved neurological function. proportion experiencing relapses dropped markedly 61.2% 14.3% (p < 0.001). results showed significant reductions new or enlarging T2 lesions 68.4% 27.6% 0.001) gadolinium-enhancing 44.9% 15.3% Patients previously treated natalizumab exhibited greater reduction scores (-1.0 0.8; compared other treatments. Multivariate regression identified (β 0.65; 0.001), previous use -0.30; 0.013), age diagnosis 0.02; 0.048) predictors scores. While markers active decreased, brain atrophy increased 31.6% 43.9% (not statistically significant; 0.105). SPMS had higher rates (61.1% vs. 25.0%; 0.007) years (100.0% 31.3%; RRMS Conclusions: Ocrelizumab effectively reduced both Significant observed. Previous treatment was associated improvements. Despite these benefits, neurodegeneration, particularly patients, underscores need for additional strategies targeting neurodegenerative aspects MS.

Язык: Английский

Процитировано

0